Novo-CSO: It is all on a very speculative level
According to Novo Nordisk’s CSO, Mads Krogsgaard, a range of studies and the company’s own Victoza database of 1 million patients show no connection between the diabetes drug and pancreatitis, as suggested by a recent scientific study.
by Stefan Singh Kailay
“This study has no implications. It is merely one among a range of studies, of which I can quote from the first five that show no connection between the drug class Victoza belongs to and the occurrence of pancreatitis.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
